Natixis Advisors LLC decreased its holdings in GSK plc (NYSE:GSK - Free Report) by 31.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 343,334 shares of the pharmaceutical company's stock after selling 157,161 shares during the quarter. Natixis Advisors LLC's holdings in GSK were worth $11,612,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in GSK. Indiana Trust & Investment Management Co boosted its stake in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust purchased a new position in shares of GSK in the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. boosted its stake in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. boosted its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after purchasing an additional 302 shares during the period. Finally, Sierra Ocean LLC purchased a new position in GSK in the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 15.74% of the company's stock.
GSK Stock Down 0.5 %
GSK stock traded down $0.19 during midday trading on Friday, reaching $39.22. 4,020,576 shares of the company were exchanged, compared to its average volume of 4,345,710. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The stock's 50-day simple moving average is $36.66 and its 200 day simple moving average is $36.92. The company has a market cap of $81.18 billion, a price-to-earnings ratio of 24.67, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.
GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current year.
GSK Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.01%. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is presently 98.74%.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on GSK. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $43.25.
Read Our Latest Research Report on GSK
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
